Moreover, ERα+ subtype shows the highest sensitivity to CDK inhibitors, possibly due to the hyperactivation of CDK4/6, while palbociclib showed no antiproliferative effect in Rb-deficient MDA-MB-468 (ERα−) human breast cancer cell lines [8, 26–28]. This evidence concerns the gene ESR1 and breast carcinoma.